ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2025
The Effect of Pomegranate Tea on the Clinical Outcomes and Symptom Alleviation in COVID-19 Patients: A Double-Blind Randomized Clinical Trial.
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Effect of Pomegranate Tea on the Clinical Outcomes and Symptom Alleviation in COVID-19 Patients: A Double-Blind Randomized Clinical Trial.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: COVID-19, caused by SARS-CoV-2, emerged as a global pandemic in late 2019, leading to significant health and societal impacts. Treatment challenges have emerged as a result of viral mutations and the strain on healthcare resources, further intensified by the consequences of long-term COVID-19. Recent studies suggest pomegranate ( Methods: This double-blinded randomized clinical trial evaluated the clinical characteristics of hospitalized COVID-19 patients. Pomegranate was sourced and processed into a standardized aqueous extract, with a placebo prepared to match its appearance. Eligible participants with confirmed COVID-19 pneumonia were randomized into intervention and placebo groups based on their respiratory support needs. Both groups received treatment during their hospital stay and continued postdischarge until symptom resolution. Standard treatment protocols were followed for all participants. Results: This double-blinded randomized clinical trial evaluated the clinical characteristics of 66 hospitalized COVID-19 patients. The median age of participants was 56 years, and demographics were similar across groups. Notably, 58.7% had symptom onset within the last 10 days. There were statistically significant differences in baseline laboratory markers or primary outcomes, including hospitalization duration and time to improvement. Secondary outcomes similarly demonstrated no significant differences in mortality, respiratory support duration, severity of clinical symptoms, or adverse effects. Conclusion: This study finds no significant advantage of pomegranate tea in managing COVID-19 but highlights the inherent challenges in researching emerging infectious diseases. Our research highlights the necessity of continuously refining methodologies and adapting to the dynamic nature of emerging pathogens. Such efforts are essential for advancing the search for effective treatments and ultimately enhancing patient care. These findings contribute critically to the ongoing exploration of therapeutic strategies against viral infections, fostering a deeper understanding of potential interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.